vs
Bank of Marin Bancorp（BMRC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是Bank of Marin Bancorp的1.0倍（$35.5M vs $34.1M），Bank of Marin Bancorp净利率更高（24.9% vs -304.2%，领先329.2%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 23.3%）
美 洲 河 银 行 是 一 家 社 区 银 行，1983 年 由 首 任 行 长 兼 首 席 执 行 官 Robert H. Daneke 与 首 任 董 事 会 主 席 Bill L. Withrow 共 同 创 立，服 务 于 美 国 加 利 福 尼 亚 州 大 萨 克 拉 门 托 地 区。截 至 2019 年，该 行 在 北 加 州 共 运 营 十 家 网 点，提 供 企 业 及 个 人 金 融 服 务，曾 是 American River Bankshares 的 全 资 子 公 司。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BMRC vs RXRX — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.1M | $35.5M |
| 净利润 | $8.5M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 24.9% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 74.5% | 39.6% |
| 每股收益（稀释后） | $0.53 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $34.1M | — | ||
| Q4 25 | $27.0M | $35.5M | ||
| Q3 25 | $30.9M | $5.2M | ||
| Q2 25 | $10.3M | $19.2M | ||
| Q1 25 | $27.8M | $14.7M | ||
| Q4 24 | $22.2M | $4.5M | ||
| Q3 24 | $27.2M | $26.1M | ||
| Q2 24 | $22.5M | $14.4M |
| Q1 26 | $8.5M | — | ||
| Q4 25 | $-39.5M | $-108.1M | ||
| Q3 25 | $7.5M | $-162.3M | ||
| Q2 25 | $-8.5M | $-171.9M | ||
| Q1 25 | $4.9M | $-202.5M | ||
| Q4 24 | $6.0M | $-178.9M | ||
| Q3 24 | $4.6M | $-95.8M | ||
| Q2 24 | $-21.9M | $-97.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
| Q1 26 | — | — | ||
| Q4 25 | -212.6% | -304.8% | ||
| Q3 25 | 31.1% | -3327.6% | ||
| Q2 25 | -108.8% | -916.8% | ||
| Q1 25 | 23.3% | -1297.9% | ||
| Q4 24 | 43.5% | -4042.4% | ||
| Q3 24 | 25.7% | -377.1% | ||
| Q2 24 | -153.0% | -697.4% |
| Q1 26 | 24.9% | — | ||
| Q4 25 | -146.5% | -304.2% | ||
| Q3 25 | 24.3% | -3135.3% | ||
| Q2 25 | -82.9% | -894.2% | ||
| Q1 25 | 17.5% | -1373.3% | ||
| Q4 24 | 27.1% | -3935.5% | ||
| Q3 24 | 16.8% | -367.5% | ||
| Q2 24 | -97.5% | -676.6% |
| Q1 26 | $0.53 | — | ||
| Q4 25 | $-2.48 | $-0.17 | ||
| Q3 25 | $0.47 | $-0.36 | ||
| Q2 25 | $-0.53 | $-0.41 | ||
| Q1 25 | $0.30 | $-0.50 | ||
| Q4 24 | $0.38 | $-0.56 | ||
| Q3 24 | $0.28 | $-0.34 | ||
| Q2 24 | $-1.36 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $394.5M | $1.1B |
| 总资产 | $3.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
| Q1 26 | $394.5M | — | ||
| Q4 25 | $394.7M | $1.1B | ||
| Q3 25 | $443.8M | $1.0B | ||
| Q2 25 | $438.5M | $919.1M | ||
| Q1 25 | $439.6M | $933.9M | ||
| Q4 24 | $435.4M | $1.0B | ||
| Q3 24 | $437.0M | $524.6M | ||
| Q2 24 | $434.9M | $584.4M |
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $1.5B | ||
| Q3 25 | $3.9B | $1.4B | ||
| Q2 25 | $3.7B | $1.3B | ||
| Q1 25 | $3.8B | $1.3B | ||
| Q4 24 | $3.7B | $1.4B | ||
| Q3 24 | $3.8B | $726.5M | ||
| Q2 24 | $3.7B | $775.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $39.1M | $-46.1M | ||
| Q3 25 | $12.5M | $-117.4M | ||
| Q2 25 | $8.0M | $-76.4M | ||
| Q1 25 | $4.9M | $-132.0M | ||
| Q4 24 | $28.4M | $-115.4M | ||
| Q3 24 | $9.9M | $-59.2M | ||
| Q2 24 | $3.4M | $-82.2M |
| Q1 26 | — | — | ||
| Q4 25 | $37.3M | $-47.3M | ||
| Q3 25 | $12.1M | $-117.6M | ||
| Q2 25 | $7.1M | $-79.6M | ||
| Q1 25 | $4.6M | $-133.8M | ||
| Q4 24 | $27.8M | $-116.7M | ||
| Q3 24 | $9.8M | $-63.8M | ||
| Q2 24 | $3.4M | $-83.4M |
| Q1 26 | — | — | ||
| Q4 25 | 138.1% | -133.1% | ||
| Q3 25 | 39.0% | -2272.5% | ||
| Q2 25 | 68.7% | -413.9% | ||
| Q1 25 | 16.6% | -907.4% | ||
| Q4 24 | 125.7% | -2567.7% | ||
| Q3 24 | 36.0% | -244.6% | ||
| Q2 24 | 15.0% | -578.5% |
| Q1 26 | — | — | ||
| Q4 25 | 6.7% | 3.5% | ||
| Q3 25 | 1.3% | 4.7% | ||
| Q2 25 | 9.4% | 16.4% | ||
| Q1 25 | 1.1% | 12.4% | ||
| Q4 24 | 2.3% | 28.6% | ||
| Q3 24 | 0.4% | 17.5% | ||
| Q2 24 | 0.4% | 8.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 4.73× | — | ||
| Q3 24 | 2.16× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRC
| Net Interest Income | $30.3M | 89% |
| Noninterest Income | $3.8M | 11% |
RXRX
暂无分部数据
